Keyphrases
Bronchiectasis
100%
Hazard Ratio
24%
Confidence Interval
23%
Treatment Response
21%
Rate Ratio
20%
India
17%
Nontuberculous Mycobacterial Lung Disease
17%
Respiratory Research
17%
Chronic Obstructive Pulmonary Disease
17%
EMBARC
17%
Symptom Response
17%
Symptom Exacerbation
17%
Multi-cohort Studies
17%
Clinical Outcomes
17%
Proteomics
17%
Blood Eosinophil Count
17%
Symptomatic Patients
17%
Sputum
17%
AGREE II Tool
17%
Exacerbation Rate
15%
Severe Exacerbations
14%
Mycobacterium Tuberculosis (M. tb)
14%
Symptom Burden
13%
Daily Symptoms
13%
Cystic Fibrosis
12%
Risk Factors
10%
Symptom Score
8%
Unmet Needs
8%
High-score
8%
Randomized Clinical Trial
8%
Observational Cohort
8%
AGREE II
8%
Inhaled Mannitol
8%
Stakeholder Participation
8%
Editorial Independence
8%
Clinical Practice Guidelines
8%
Quality Assessment
8%
Updated Guidelines
8%
Grading System
8%
Eosinophil Count
7%
Poor Outcome
7%
Mortality Hazard
7%
Protein Profile
7%
Increased Mortality
6%
Pseudomonas Aeruginosa Infection
6%
Nontuberculous Mycobacterial Infection
5%
Sputum Microbiome
5%
Biochemistry, Genetics and Molecular Biology
Pseudomonas aeruginosa
23%
Proteomics
21%
Infectious Agent
21%
Mucin
17%
Klebsiella pneumoniae
17%
Cigarette Smoking
17%
Randomized Clinical Trial
17%
Cystic Fibrosis
17%
Stakeholder Engagement
17%
Observational Study
17%
Comorbidity
17%
Mannitol
17%
Microbiome
14%
Dry Powder
5%
Medicine and Dentistry
Bronchiectasis
44%
Chronic Obstructive Pulmonary Disease
28%
Sputum
21%
Proteomics
19%
Critical Appraisal
17%
Silo-Filler's Disease
17%
Cystic Fibrosis
10%
Randomized Clinical Trial
8%
Stakeholder Engagement
8%
Biological Marker
5%